| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-885
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2013-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102418979-B1 |
| titleOfInvention |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| abstract |
The present disclosure provides a cancer patient comprising administering to the cancer patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or administering such Ab in combination with an anti-CTLA-4 Ab. A method for immunotherapy of The present disclosure also provides a method for selecting a patient that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from a cancer patient expressing PD-L1 on their cell surface exceeds a predetermined threshold level. ; and administering an anti-PD-1 Ab to the selected subject. The present disclosure additionally provides rabbit mAbs that specifically bind to cell surface-expressed PD-L1 antigen in FFPE tissue samples, and anti-PD-L1 Abs provided above for assessing cell surface expression in FFPE tissues. An automated IHC method is provided. |
| priorityDate |
2012-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |